Nektar Therapeutics said this week that it has named Howard Robin as its new president and CEO, effective Jan. 15.
Robin currently serves as president and CEO of Sirna Therapeutics, which was acquired by Merck for $1.1 billion in cash (see RNAi News, 1/4/2007).
Prior to heading up Sirna, Robin was corporate vice president and general manager of Berlex Laboratories’ US therapeutics division.
Acorda Therapeutics said this week that it has appointed Barry Greene to its board of directors.
Greene is currently the COO of Alnylam Pharmaceuticals.
Bio-Rad said last week that Philip Padou, one of the company’s directors, has died at the age of 72.
Padou had sat on Bio-Rad’s board since 1980. The company said it plans to seek a replacement.